Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis

He Li, Jinrong Yang, Yun Tang et al. Nov 03, 2025 pp. 6303-6303 10.1182/blood-2025-6303

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome driven by cytokine storms (e....

GVHD intel 1.0: A scalable, HLA-enhanced machine learning model for predicting acute and chronic GVHD

Naveed Syed, Mohamed Abu Haleeqa, Fatema Al Kaabi et al. Nov 03, 2025 pp. 4243-4243 10.1182/blood-2025-4243

Abstract Background: Graft-versus-host disease (GVHD) remains the leading cause of non-relapse morbidity and mortality in allogeneic hematop...

Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma

Danielle Thor, Mahija Cheekati, Ben Brik et al. Nov 03, 2025 pp. 2759-2759 10.1182/blood-2025-2759

Abstract Introduction: The emergence of novel immunotherapies has transformed the treatment landscape for hematological malignancies such as...

The novel ims / IMWG high-risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Ioannis Ntanasis-Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou et al. Nov 03, 2025 pp. 3986-3986 10.1182/blood-2025-3986

Abstract Background: Renal impairment (RI) is common in newly diagnosed multiple myeloma (NDMM). Since serum β2-microglobulin (sb2m) is a mar...

Ropeginterferon alfa-2b in 248 patients with polycythemia vera: Results from the italian cohort of a prospective, non-interventional, post-authorization study (ROPEG-PV)

Tiziano Barbui, Arianna Ghirardi, Francesca Fenili et al. Nov 03, 2025 pp. 5572-5572 10.1182/blood-2025-5572

Abstract Introduction: Ropeginterferon alfa-2b (Ropeg) was approved in Europe (2019) and in the US (2021) for treating polycythemia vera (PV...

Association of factor VIII inhibitors with genetic variants implicated in immune dysregulation

Silvia Juarez Rojas, Zhuangzhuang Geng, Bhavya Doshi Nov 03, 2025 pp. 3057-3057 10.1182/blood-2025-3057

Abstract Introduction: Congenital hemophilia A (HA) is a severe bleeding disorder that results from the deficiency of coagulation factor VII...

Efficacy and safety of romiplostim N01 for second-line treatment of pediatric immune thrombocytopenia: A multicenter prospective observational study

Aijun Zhang, Xiaomei Yang, Xudong Wang et al. Nov 03, 2025 pp. 3040-3040 10.1182/blood-2025-3040

Abstract Background: Pediatric immune thrombocytopenia (ITP) is an autoimmune disorder characterized by thrombocytopenia and an increased ri...

Pneumocystis jirovecii pneumonia in patients with hematologic malignancy: Risky business, but for whom?

Jared Eckman, Alex Romero, Erika Orner et al. Nov 03, 2025 pp. 6313-6313 10.1182/blood-2025-6313

Abstract Background: Pneumocystis jirovecii pneumonia (PJP) is a serious respiratory infection that can have significant...

Blast clearance dynamics and time to response across IDH1- and IDH2-mutated AML

Mohamad Sheikh Najeeb, Oudai Alkabbani, Rong He et al. Nov 03, 2025 pp. 7045-7045 10.1182/blood-2025-7045

Abstract Background: Isocitrate dehydrogenase (IDH) mutations are frequently implicated in the development of acute myel...

Interim analysis of the phase II study of glofitamab, lenaliomide and venetoclax (GLOVe) in untreated patients w/ high-risk mantle cell lymphoma. response and safety outcomes after the completion of stage 1 of 2 enrollment.

Tycel Phillips, Lu Chen, Tiffanie Barnhizer et al. Nov 03, 2025 pp. 883-883 10.1182/blood-2025-883

Abstract Background: Mantle Cell Lymphoma (MCL) has no established standard of care (SOC) in the front-line (1L) setting. Recent studies - T...

Safety and efficacy of INCA033989, a novel first in class mutant calreticulin-specific monoclonal antibody, in patients with essential thrombocythemia

Vikas Gupta, John Mascarenhas, Haris Ali et al. Nov 03, 2025 pp. 1024-1024 10.1182/blood-2025-1024

Abstract Background: Essential thrombocythemia (ET) is a myeloproliferative neoplasm with increased risk of thrombosis, hemorrhage, and tran...

Initial treatment of chronic lymphocytic leukemia with low-dose high-frequency rituximab followed by addition of acalabrutinib

Charles Chu, Clare Heffernan, Nydia Jaimes-Delgadillo et al. Nov 03, 2025 pp. 2131-2131 10.1182/blood-2025-2131

Abstract Introduction: Rituximab is effective at removing circulating CLL cells by inducing antibody-dependent cellular phagocytosis (ADCP)....

CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma

Lydia Lee, Amatta Mirandari, Aditya Prabu et al. Nov 03, 2025 pp. 4173-4173 10.1182/blood-2025-4173

Abstract Introduction: BCMA directed CAR-T cell therapy for multiple myeloma (MM) shows promise, but relapses continue to occur despite deep...

Optimizing ELN 2022: Developing and validating a dynamic prognostic model for AML using platelet change rates and MRD kinetics

Ning Liu, Menghao Wei, Xiaoman Sun et al. Nov 03, 2025 pp. 1612-1612 10.1182/blood-2025-1612

Abstract Background Acute myeloid leukemia (AML) shows significant clinical and molecular diversity[1]. The ELN 2022 ris...

Raising the bar in maternofetal hematology: Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds

Daniel Wang, Manraj Sra, Satoko Ito et al. Nov 03, 2025 pp. 598-598 10.1182/blood-2025-598

Abstract Introduction: Iron deficiency (ID) is among the five leading causes of years lived with disability in women of reproductive age wor...

TCL1A polymorphism predicts AML progression in myeloid neoplasms

Alfonso Molina, Alexandria Jensen, Jayakrishnan Gopakumar et al. Nov 03, 2025 pp. 3854-3854 10.1182/blood-2025-3854

Abstract Background: Clonal hematopoiesis is driven by somatic mutations in hematopoietic stem cells that confer their fitness advantage and...

Circulating immune profile in patients with amyloidosis

Janine Joseph, Joseph Tario, Han Yu et al. Nov 03, 2025 pp. 5748-5748 10.1182/blood-2025-5748

Abstract Introduction Although both light-chain (AL) and transthyretin (ATTR) amyloidosis involve accumulation of misfolded proteins in one...

Validation of the boscore model for predicting invasive mold disease in Chinese patients with hematological malignancies undergoing chemotherapy: A single-center retrospective study

Minghui Duan, Wen-xin Li Nov 03, 2025 pp. 7947-7947 10.1182/blood-2025-7947

Abstract Background: Patients with hematological malignancies (HM) are at high risk of invasive mold disease (IMD) due to chemotherapy-induc...

Clinical characteristics of early mortality and critical illness in acute promyelocytic leukemia patients

Peiqi Liang, Jianhong Fu, Qian Li et al. Nov 03, 2025 pp. 6941-6941 10.1182/blood-2025-6941

Abstract Results: Among the 408 newly diagnosed APL patients, 27 experienced early deathand the early mortality rate was 62%. The median tim...

Impact of metformin on the incidence of thrombotic events in ­older patients with polycythemia vera and essential thrombocythemia in the United States

Jessica Stempel, Rong Wang, Rory Shallis et al. Nov 03, 2025 pp. 6392-6392 10.1182/blood-2025-6392

Abstract XM, NP co-senior authors Background Patients (pts) with Philadelphia chromosome negative myeloproliferative neo...

Clpx plays pleiotropic roles in heme synthesis and erythropoiesis

Muhammad Ishfaq, Samantha Gillis, Samreen Salam et al. Nov 03, 2025 pp. 525-525 10.1182/blood-2025-525

Abstract Differentiating red cells synthesize large quantities of heme for hemoglobin production, requiring tight coordination between mitoc...

Long-term outcomes with emicizumab prophylaxis in patients with hemophilia a in China

Yuan Xu, Ying Wang, Ningling Wang et al. Nov 03, 2025 pp. 1287-1287 10.1182/blood-2025-1287

Abstract Introduction: Emicizumab, a bispecific monoclonal antibody that bridges activated factor IX and factor X, has emerged as an effecti...

Partial splenic embolization to manage thrombocytopenia in cancer patients: Case series and review of the literature

Zahra Ridha, Kiat Tsong Tan, Michael Connolly et al. Nov 03, 2025 pp. 6599-6599 10.1182/blood-2025-6599

Abstract Introduction Thrombocytopenia is a common complication of cancer and its management (Liebman, 2014). Alleviatin...

Loss of transcription factor myb drives an immune differentiated megakaryocyte phenotype

Michael Malloy, Sara Ture, James Palis et al. Nov 03, 2025 pp. 4934-4934 10.1182/blood-2025-4934

Abstract Bulk and single cell RNA-sequencing (RNA-seq) of lung and bone marrow (BM) megakaryocytes (Mks) revealed the transcription factor M...

Preliminary results of a first-in-human, Phase 1 study of GLB-002, a novel molecular glue degrader of IKZF1/3, in patients with relapsed or refractory non-Hodgkin lymphoma

Ningjing Lin, Keshu Zhou, quande Lin et al. Nov 03, 2025 pp. 5368-5368 10.1182/blood-2025-5368

Abstract Introduction GLB-002 is a novel cereblon E3 ubiquitin ligase modulator selectively targeting Ikaros (IKZF1) and Aiolos (IKZF3) for...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page